What published data support R-CEP in DLBCL? 2. How many patients with DLBCL have they treated with it? 3. Is the...

I appreciate your detailed questions about R-CEP (rituximab, cyclophosphamide, epirubicin, prednisone) in DLBCL. Let me address what the published evidence shows:

1. Published Data Supporting R-CEP in DLBCL

R-CEP is not a standard first-line regimen in DLBCL according to major guidelines. Here's what the evidence shows:

• NCCN Guidelines for DLBCL recommend R-CHOP as the standard of care for fit patients, with alternatives like R-CHOP plus radiation for early-stage disease
• ASCO Guidelines similarly endorse R-CHOP as the primary approach
• R-CEP (substituting epirubicin for doxorubicin and omitting vincristine) has limited prospective trial data in DLBCL specifically
• Most published experience with R-CEP comes from older studies or retrospective analyses, not large randomized trials

2. Patient Numbers Treated with R-CEP

I don't have access to specific institutional data on how many patients have been treated with R-CEP at any particular center. This would require:

• Institutional case series or retrospective reviews
• Direct inquiry to the treating institution
• Published case reports or small series (which are limited)

3. Purpose: Vincristine Neurotoxicity Avoidance

This is a reasonable clinical hypothesis, but it's important to note:

• Vincristine neurotoxicity (peripheral neuropathy) is a known toxicity of R-CHOP, particularly with cumulative doses
• Omitting vincristine would theoretically reduce this risk
• However, doxorubicin cardiotoxicity becomes the limiting factor instead
• The trade-off between different toxicities (neuropathy vs. cardiac) isn't clearly established as favorable in published data

4. Cure Rate Comparisons

This is where I need to be direct: Published comparative cure rate data for R-CEP vs. R-CHOP or Pola-R-CHP in DLBCL does not exist in major trials.

Here's why this matters:

R-CHOP remains standard because:

• RICOVER-60 trial and other large studies established R-CHOP efficacy
• 5-year overall survival with R-CHOP: approximately 60-70% in fit patients (varies by IPI score)
• This is the benchmark against which alternatives are measured

Pola-R-CHP (polatuzumab vedotin + R-CHP):

• GO29365 trial showed improved PFS vs. R-CHOP in previously untreated DLBCL
• FDA-approved for first-line DLBCL in fit patients
• Cure rates: improved but still evolving with longer follow-up

R-CEP specifically:

• No large randomized trial comparing R-CEP to R-CHOP or Pola-R-CHP
• No published cure rate estimates specific to this regimen
• Any comparison would be institutional or anecdotal, not evidence-based

---

What [facility removed]ally

If you or someone you know is being considered for R-CEP instead of standard regimens, important questions for the oncologist would be:

1. Why R-CEP specifically? (Is there a contraindication to doxorubicin or vincristine?)
2. What is the evidence base for this choice in my specific situation?
3. How does the expected efficacy compare to R-CHOP or Pola-R-CHP?
4. What are the specific toxicity concerns driving this decision?
5. Is this part of a clinical trial, or an institutional variation?

---

Sources:

• NCCN Guidelines for Hodgkin and Non-Hodgkin Lymphomas (current version)
• ASCO Guidelines on DLBCL treatment
• GO29365 Trial (Polatuzumab vedotin in DLBCL)
• RICOVER-60 Trial (R-CHOP efficacy benchmark)

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.